Literature DB >> 27499713

A Personalized Approach to Managing Inflammatory Bowel Disease.

Michael J Kingsley1, Maria T Abreu1.   

Abstract

The management of inflammatory bowel disease (IBD) requires a personalized approach to treat what is a heterogeneous group of patients with inherently variable disease courses. In its current state, personalized care of the IBD patient involves identifying patients at high risk for rapid progression to complications, selecting the most appropriate therapy for a given patient, using therapeutic drug monitoring, and achieving the individualized goal that is most appropriate for that patient. The growing body of research in this area allows clinicians to better predict outcomes for individual patients. Some paradigms, especially within the realm of therapeutic drug monitoring, have begun to change as therapy is targeted to individual patient results and goals. Future personalized medical decisions may allow specific therapeutic plans to draw on serologic, genetic, and microbial data for Crohn's disease and ulcerative colitis patients.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; biomarkers; personalized medicine; serologic markers; therapeutic drug monitoring; ulcerative colitis

Year:  2016        PMID: 27499713      PMCID: PMC4973561     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  68 in total

1.  A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

2.  Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms.

Authors:  Mary E Sherlock; Thomas Walters; Merit M Tabbers; Karen Frost; Mary Zachos; Aleixo Muise; Elena Pope; Anne M Griffiths
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-05       Impact factor: 2.839

Review 3.  Therapeutic drug monitoring of biologics for inflammatory bowel disease.

Authors:  Jean-Frédéric Colombel; Brian G Feagan; William J Sandborn; Gert Van Assche; Anne M Robinson
Journal:  Inflamm Bowel Dis       Date:  2011-10-21       Impact factor: 5.325

4.  High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.

Authors:  Steven A Hendler; Benjamin L Cohen; Jean-Frédéric Colombel; Bruce E Sands; Lloyd Mayer; Shradha Agarwal
Journal:  J Crohns Colitis       Date:  2014-12-24       Impact factor: 9.071

5.  Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; H Hildebrand; U Fagerberg; S Almer
Journal:  Aliment Pharmacol Ther       Date:  2006-07-15       Impact factor: 8.171

6.  The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

Authors:  Bella Ungar; Yehuda Chowers; Miri Yavzori; Orit Picard; Ella Fudim; Ofir Har-Noy; Uri Kopylov; Rami Eliakim; Shomron Ben-Horin
Journal:  Gut       Date:  2013-09-16       Impact factor: 23.059

7.  Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes.

Authors:  Steven R Brant; Michael F Picco; Jean-Paul Achkar; Theodore M Bayless; Sunanda V Kane; Aaron Brzezinski; Franklin J Nouvet; Denise Bonen; Amir Karban; Themistocles Dassopoulos; Reda Karaliukas; Terri H Beaty; Stephen B Hanauer; Richard H Duerr; Judy H Cho
Journal:  Inflamm Bowel Dis       Date:  2003-09       Impact factor: 5.325

8.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

Authors:  Xavier Roblin; Hubert Marotte; Melanie Rinaudo; Emilie Del Tedesco; Amelie Moreau; Jean Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Stephane Paul
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

9.  Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease.

Authors:  Wei Wang; Liping Chen; Rui Zhou; Xiaobing Wang; Lu Song; Sha Huang; Ge Wang; Bing Xia
Journal:  J Clin Microbiol       Date:  2013-11-13       Impact factor: 5.948

Review 10.  Therapeutic drug monitoring in patients with inflammatory bowel disease.

Authors:  Andres J Yarur; Maria T Abreu; Amar R Deshpande; David H Kerman; Daniel A Sussman
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

View more
  6 in total

Review 1.  Eosinophilic esophagitis: What can we learn from Crohn's disease?

Authors:  Javier Molina-Infante; Alain M Schoepfer; Alfredo J Lucendo; Evan S Dellon
Journal:  United European Gastroenterol J       Date:  2016-09-29       Impact factor: 4.623

2.  Chronic Model of Inflammatory Bowel Disease in IL-10-/- Transgenic Mice: Evaluation with Ultrasound Molecular Imaging.

Authors:  Huaijun Wang; Jose G Vilches-Moure; Samir Cherkaoui; Isabelle Tardy; Charline Alleaume; Thierry Bettinger; Amelie Lutz; Ramasamy Paulmurugan
Journal:  Theranostics       Date:  2019-08-14       Impact factor: 11.556

3.  US Molecular Imaging of Acute Ileitis: Anti-Inflammatory Treatment Response Monitored with Targeted Microbubbles in a Preclinical Model.

Authors:  Huaijun Wang; Jean-Marc Hyvelin; Stephen A Felt; Ismayil Guracar; Jose G Vilches-Moure; Samir Cherkaoui; Thierry Bettinger; Lu Tian; Amelie M Lutz; Jürgen K Willmann
Journal:  Radiology       Date:  2018-07-24       Impact factor: 29.146

Review 4.  Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases.

Authors:  Alicja Derkacz; Pawel Olczyk; Katarzyna Komosinska-Vassev
Journal:  Dis Markers       Date:  2018-06-11       Impact factor: 3.434

5.  Contrast Enhanced Ultrasound Molecular Imaging of Spontaneous Chronic Inflammatory Bowel Disease in an Interleukin-2 Receptor α-/- Transgenic Mouse Model Using Targeted Microbubbles.

Authors:  Huaijun Wang; Jose G Vilches-Moure; Thierry Bettinger; Samir Cherkaoui; Amelie Lutz; Ramasamy Paulmurugan
Journal:  Nanomaterials (Basel)       Date:  2022-01-17       Impact factor: 5.076

6.  Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease.

Authors:  Katsuyoshi Matsuoka; Makoto Naganuma; Toshifumi Hibi; Hirohito Tsubouchi; Kiyoshi Oketani; Toshinori Katsurabara; Seiichiro Hojo; Osamu Takenaka; Tetsu Kawano; Toshio Imai; Takanori Kanai
Journal:  J Gastroenterol Hepatol       Date:  2021-03-31       Impact factor: 4.029

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.